Clinical Trial

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma (R/R NHL) to determine if ARV-393 may be a possible treatment option. ARV-393 is thought to work by breaking down a protein present in many types of non-Hodgkins lymphomas, which may prevent, slow or stop tumor growth. This is the first time ARV-393 will be used by people. The investigational drug will be given as an oral tablet.
Protocol Amendment History 15 amendments
This ClinicalTrials.gov record has been amended 15 times since 2024-04-30; most recent amendment 2026-02-06.
Status change: Not Yet Recruiting → Recruiting 2024-09-05
Status change: Recruiting → Not Yet Recruiting 2024-08-06
Trial Details
NCT Number NCT06393738
Lead Sponsor Arvinas Inc.
Conditions Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Enrollment 255 participants
Start Date 2024-09-05
Primary Completion 2028-03 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2026-02-10